Mumefural Improves Blood Flow in a Rat Model of FeCl 3 -Induced Arterial Thrombosis

• Published in: Nutrients Vol. 12; no. 12
• Main Authors: Bang, Jihye, Jeon, Won Kyung
• Format: Journal Article
• Language: English
• Published: Switzerland 10.12.2020
• Subjects: Animals; Blood Circulation - drug effects; Citric Acid - analogs & derivatives; Citric Acid - pharmacology; Disease Models, Animal; Ferric Compounds; Fibrinolytic Agents - pharmacology; Furans - pharmacology; Plant Extracts - pharmacology; Platelet Activation - drug effects; Prunus; Rats; Rats, Sprague-Dawley; Signal Transduction - drug effects; Thrombosis - chemically induced; Thrombosis - drug therapy; FeCl3-induced arterial thrombosis; platelet activation; mumefural
• ISSN: 2072-6643

Mumefural (MF), a bioactive component of the processed fruit of Sieb. et Zucc, is known to inhibit platelet aggregation induced by agonists in vitro. In this study, we investigated the anti-thrombotic effects of MF using a rat model of FeCl -induced arterial thrombosis. Sprague-Dawley rats were intraperitoneally injected with MF (0.1, 1, or 10 mg/kg) 30 min before 35% FeCl treatment to measure the time to occlusion using a laser Doppler flowmeter and to assess the weight of the blood vessels containing thrombus. MF treatment significantly improved blood flow by inhibiting occlusion and thrombus formation. MF also prevented collagen fiber damage in injured vessels and inhibited the expression of the platelet activation-related proteins P-selectin and E-selectin. Moreover, MF significantly reduced the increased inflammatory signal of nuclear factor (NF)-κB, toll-like receptor 4 (TLR4), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 in blood vessels. After administration, MF was detected in the plasma samples of rats with a bioavailability of 36.95%. Therefore, we suggest that MF may improve blood flow as a candidate component in dietary supplements for improving blood flow and preventing blood circulation disorders.